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Abstract
Ivermectin is an old, common, and classic anti-parasite drug, which has been
found to have a broad-spectrum anti-cancer effect on multiple human cancers. This
chapter will focus on the anti-cancer effects of ivermectin on ovarian cancer. First,
ivermectin was found to suppress cell proliferation and growth, block cell cycle
progression, and promote cell apoptosis in ovarian cancer. Second, drug pathway
network, qRT-PCR, and immunoaffinity blot analyses found that ivermectin acts
through molecular networks to target the key molecules in energy metabolism
pathways, including PFKP in glycolysis, IDH2 and IDH3B in Kreb’s cycle, ND2,
ND5, CYTB, and UQCRH in oxidative phosphorylation, and MCT1 and MCT4 in
lactate shuttle, to inhibit ovarian cancer growth. Third, the integrative analysis of
TCGA transcriptomics and mitochondrial proteomics in ovarian cancer revealed
that 16 survival-related lncRNAs were mediated by ivermectin, SILAC quantitative
proteomics analysis revealed that ivermectin extensively inhibited the expressions
of RNA-binding protein EIF4A3 and 116 EIF4A3-interacted genes including those
key molecules in energy metabolism pathways, and also those lncRNAs regulated
EIF4A3-mRNA axes. Thus, ivermectin mediated lncRNA-EIF4A3-mRNA axes in
ovarian cancer to exert its anticancer capability. Further, lasso regression identified
the prognostic model of ivermectin-related three-lncRNA signature (ZNRF3-AS1,
SOS1-IT1, and LINC00565), which is significantly associated with overall survival
and clinicopathologic characteristics in ovarian cancer patients. These ivermectin-
related molecular pattern alterations benefit for prognostic assessment and person-
alized drug therapy toward 3P medicine practice in ovarian cancer.
Keywords: ovarian cancer, ivermectin, anti-cancer effect, therapeutic targets,
prognostic assessment, biomarker, predictive preventive personalized medicine
1. Introduction
Ivermectin is chemically derived from avermectin that was discovered and
isolated from soil in Jan by Omura in 1973 [1]. It was approved by Federal Drug
Administration (FDA) to use for anti-parasite drug in 1987, which has significantly
improved global public health as an antiparasite medicine [2]. In 2015, its discovers
Drs. Omura and Campbell earned the Nobel Prize in physiology or medicine [2].
Recent years, many studies have demonstrated that ivermectin has extensive roles
in anti-bacteria, anti-virus, and anticancer, except for its anti-parasite effects [3–5].
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Its anticancer effect has been shown by many in vitro and in vivo experiments in
multiple cancers, including ovarian cancer, breast cancer, triple-negative breast
cancer, cervical cancer, lung cancer, gastric cancer, colon cancer, glioblastoma,
melanoma, and leukemia [4, 6], with a wide safe and clinically reachable drug
concentration of anticancer according to its pharmacokinetic range in treatment of
a parasite-infected patient [7]. It offers a promising opportunity to develop a new
anticancer drug via drug repositioning of this existing compound with confirmed
clinical safety [8].
Ovarian cancer, a very common cancer with high mortality and poor survival in
women [9, 10], are involved in multiple signaling pathway network changes
[11, 12]. Many intracellular molecules and signaling pathways would be the targets
of ivermectin [13]. Ivermectin have shown a potential addition role for ovarian
cancer treatment. For example, ivermectin can improve the chemosensitivity of
overran cancer via targeting Akt/mTOR signaling pathway [14], and can inhibit
PAK1-dependent growth of ovarian cancer cells via blocking the oncogenic kinase
PAK1 [15]. Ivermectin also acts as a PAK1 inhibitor to induce autophagy in breast
cancer [16]. Ivermectin can enhance p53 expression and cytochrome C release, and
reduce the expression levels of CDK2, CDK4, CDK6, Bcl-2, cyclin E, and cyclin D1
in glioblastoma, those promoted the cancer cell apoptosis [17]. Ivermectin can
inhibit cancer cell proliferation via decreasing YAP1 protein expression in the Hippo
pathway [18]. Ivermectin represses WNT-TCF pathway in WNT-TCF-dependent
disease [19]. Ivermectin can promote TFE3 (Ser321) dephosphorylation to block the
binding between TFE3 and 14-3-3, and induce TFE3 accumulation in the nucleus of
human melanoma cells [20]. Moreover, ivermectin also affects other signaling
pathway network in human cancers, including oxidative stress, mitochondrial dys-
function, angiogenesis, epithelial-mesenchymal transition, drug resistance, and
stemness in tumor [6]. Thereby, ivermectin demonstrates the potential therapeutic
efficiency in multiple malignant tumors.
This book chapter discussed the anti-cancer effects of ivermectin on ovarian
cancer in the following aspects: (i) ivermectin inhibited cell proliferation and
growth, blocked cell cycle progression, and promoted cell apoptosis in ovarian
cancer [4, 21]; (ii) ivermectin inhibited ovarian cancer growth through molecular
networks to target the key molecules in energy metabolism pathways, including
glycolysis, Kreb’s cycle, oxidative phosphorylation, and lactate shuttle pathways
[21]; (iii) Integrated omics revealed that ivermectin mediated lncRNA-EIF4A3-
mRNA axes in ovarian cancer to exert its anticancer capability [4, 13]; and (iv) lasso
regression identified the prognostic model of ivermectin-related three-lncRNA sig-
nature (ZNRF3-AS1, SOS1-IT1, and LINC00565) that is significantly related to
overall survival and clinicopathologic characteristics of ovarian cancers [4].
2. Methods
2.1 Ovarian cancer cell biological behaviors affected by ivermectin
The normal ovarian cells IOSE80 and ovarian cancer cells TOV-21 and SKOV3
were treated with ivermectin to measure ivermectin-mediated ovarian cancer cell
biological behavior changes. (i) IOSE80, TOV-21G, and SKOV3 were treated with
ivermectin (0–60 μM) for 24 h, followed by the use of CCK8 to measure the IC50 of
ivermectin in each cell. (ii) TOV-21G and SKOV3 were treated with ivermectin
(0 μM, 10 μM, 20 μM, and 30 μM) for 24 h, followed by the use of EdU assay to
measure DNA synthesis in each cell. (iii) TOV-21G and SKOV3 were treated with
ivermectin (0 μM, 10 μM, 20 μM, and 30 μM) for 48 h, followed by clonogenic
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assay to measure the in vitro effects of ivermectin in each cell. (iv)TOV-21G and
SKOV3 were treated with ivermectin (0 μM, 10 μM, 20 μM, and 30 μM) for 24 h,
followed by flow cytometry to measure cell cycle and cell apoptosis changes in each
cell. (v) When A2780 and TOV-21G seeded in 6-well plates were grown to approx-
imately 90% confluency, followed by the use of 10-μl pipette tip to make an
artificial wound, and then treated with ivermectin (0 μM, 10 μM, 20 μM, and
30 μM) for 24 h, and measure the wound healing. The relative percentage of wound
healing = (the width of wound at 0 h  the width of wound at 24 h)/the width of
wound at 0 h. The detailed procedure was described previously [4, 21].
2.2 Ivermectin-mediated pathway network predicted by ingenuity pathway
analysis
The classical pathway network analysis software, Ingenuity Pathway Analysis
(IPA) (http://www.ingenuity.com) [5] was used to predict ivermectin-related
potential target molecules in three energy metabolism pathways. For this analysis,
ivermectin and target genes in three energy metabolism pathways are all input into
the IPA tool. The detailed procedure was described previously [21]. The predicted
ivermectin-mediated targets in energy metabolism pathways were the basis for
further experiment verification.
2.3 Ivermectin-mediated target molecule changes in energy metabolism
pathways verified at the mRNA and protein levels
TOV-21G and SKOV3 were treated with ivermectin (0 μM, 10 μM, 20 μM, and
30 μM) for 24 h, and 48 h. At the 24 h time point, the RNAs were extracted for
quantitative real-time PCR (qRT-PCR) analysis to measure the mRNA expression of
target molecules (CS, PDHB, IDH2, IDH3A, IDH3B, PFKP, PKM, MCT1, MCT4,
OGDHL, ND2, ND5, CYTB, and UQCRH) in energy metabolism pathways. At the
48 h time point, the proteins were extracted for Western blot analysis to measure
the protein expression of target molecules (CS, PDHB, IDH2, IDH3A, IDH3B,
PFKP, PKM, MCT1, MCT4, OGDHL, ND2, ND5, CYTB, and UQCRH) in energy
metabolism pathways. The detailed procedure was described previously [21].
2.4 Ivermectin-mediated proteome changes in ovarian cancer identified by
SILAC-based quantitative proteomics
SILAC (stable isotope labeling with amino acids in cell culture)-based quantita-
tive proteomics was used to identified differentially expressed proteins in ovarian
cancer TOV-21G treated with and without 20 μM ivermectin [13]. The identified
differentially expressed proteins were used for molecular network and signaling
pathway analyses to obtain ivermectin-related signaling pathway networks [13].
The detailed procedure was described previously [13].
2.5 Transcriptomics and clinical data of ovarian cancer patients extracted from
TCGA database
Level 3 RNA-seq V2 transcriptomics data of 411 OC patients were extracted
from The Cancer Genome Atlas (TCGA) data portal (http://cancergenome.nih.gov/)
with the corresponding clinical data, including cancer status (with tumor or
tumor-free), clinical stage (stages IIA, IIB, IIC, IIIA, IIIB, IIIC, and IV), neoplasm
histologic grade (G1, G2, G3, G4, and GX), anatomic neoplasm subdivision (right,
left, and bilateral), age at initial pathologic diagnosis (aged from 30 to 87),
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lymphatic invasion (yes/no), primary therapy outcome success (complete remis-
sion/response, partial remission/response, progressive disease, and stable disease),
additional radiation therapy (yes/no), survival time (days), tumor residual disease
(no macroscopic disease, 1–10 mm, 11–20 mm, and > 20 mm), survival status
(0 = alive, and 1 = dead), and PANCAN (Pan-Cancer Atlas). TANRIC
(http://ibl.mdanderson.org/tanric/design/basic/index.html) was used for survival
analysis of lncRNAs in ovarian cancer. The large-scale CLIP-Seq data with starBasev
2.0 (http://starbase.sysu.edu.cn/mirCircRNA.php) was used to predict the EIF4A3-
binding mRNAs. The Kaplan–Meier method relative to the log-rank test was used
for survival analysis of mRNAs in ovarian cancers. Statistical significance was set as
p value <0.05. GenCLiP 3 (http://ci.smu.edu.cn/genclip3/analysis.php) was used
for pathway enrichment analysis of the association of EIF4A3-binding mRNAs and
patient survival rates. The detailed procedure was described previously [4].
2.6 Ivermectin-related lncRNAs verified with qRT-PCR
TRizol® Reagent (Invitrogen, CA, USA) was used to extract total RNAs of cells
TOV21G and A2780 treated with different concentration of ivermectin (0 μM,
10 μM, 20 μM, and 30 μM). The extracted total RNAs was reversely transcribed into
cDNAs for qRT-PCR analysis of each lncRNA expression, including KIF9-AS1,
HCG15, PDCD4-AS1, ZNRF3-AS1, ZNF674-AS1, LINC00565, SOS1-IT1, WWTR1-
AS1, PLCH1-AS1, LINC00517, SNHG3, STARD13-IT1, AL109767.1, HOXC-AS3,
LEMD1-AS1, and LBX2-AS1. Beta-actin was set as internal control for qRT-PCR
analysis. The detailed procedure was described previously [4].
2.7 LncRNA-based prognostic signature optimized with lasso regression for
ovarian cancers
Lasso regression means least absolute shrinkage and selection operator regres-
sion, which was used to optimize and construct lncRNA-based prognostic signature,
and the glmnet R package was used to measure the association between survival risk
and lncRNA signature in ovarian cancers. Moreover, univariate and multivariate
Cox regression, and Kaplan–Meier method were used to identify overall survival-
related clinical characteristics described above in ovarian cancers to confirm the
established lncRNA-based prognostic model. The detailed procedure was described
previously [4].
2.8 Statistical significance
Benjamini–Hochberg (FDR) for multiple testing was used to correct the p values
of IPA, GO, and KEGG analyses. Student’s t test was used for qRT-PCR and western
blot data (p < 0.05) with data expression of mean  SD (n = 3).
3. Results and discussion
3.1 Effects of ivermectin on biological behaviors of ovarian cancers
First, CCK8 experiments were used to measure cell proliferation changes
between ovarian cancer cells (SKOV3; TOV-21G) and control cells (IOSE80),
treated with and without ivermectin (Figure 1). Each type of cells was significantly
inhibited by ivermectin with a dose-dependent relationship. The IC50 (half maxi-
mal inhibitory concentration) was 29.46 μM for IOSE80 cells, 20.85 μM for SKOV3,
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and 22.54 μM for TOV-21G (Figure 1A). The IC50 of ovarian cancers were signifi-
cantly lower than the normal controls. Further, 20 μM ivermectin - slightly lower
than IC50 – can effectively inhibit ovarian cancer proliferation (Figure 1B and C)
[21]. For in vivo human trial, the highest FDA-approved ivermectin dose was
200 μg/kg for human use in anti-parasite; however, a study on 68 human subjects
found that the dose up to 2,000 μg/kg still worked well without CNS toxicity. The
mean area under the curve ratios for the 30 and 60 mg doses were 1.24 and 1.40,
indicating a minimal accumulation of ivermectin [5, 22]. These data demonstrate
that ivermectin was a well-tolerated safe drug. Second, EdU cell proliferation
experiments also confirmed that ivermectin significantly suppressed cell prolifera-
tion of ovarian cancers with a time-dependent relationship (Figure 1D-F) [21].
Third, Clonogenic survival experiments confirmed that ivermectin effectively
inhibited the formation of cell clones with a time-dependent relationship
(Figure 1G-H) [21]. Moreover, 10 μM ivermectin cannot effectively inhibit cell
proliferation of ovarian cancers, 30 μM ivermectin caused cell death of ovarian
cancers, and 20 μM ivermectin was a suitable dose to significantly suppress growth
and proliferation of ovarian cancer cells.
3.2 Effects of ivermectin on cell cycle and apoptosis in ovarian cancers
Flow cytometry was used to measure cell cycle and apoptosis of ovarian cancer
cells treated with and without ivermectin (Figure 2) [21]. First, the cell proportion
was significantly increased in G0/G phase, decreased in S phase, and no change in
G2/M phase in the high concentration (20- and 30-μM) compared to the low
concentration (0- and 10-μM) of ivermectin groups (Figure 2A-C). Second, com-
pared to control group, the proportion of apoptosis cells was significantly increased
Figure 1.
Ivermectin suppressed ovarian cancer cell proliferation in vitro, measured with CCK8 (A-C), EdU (D-F), and
clonogenic experiments (G, H). Reproduced from Li et al. [21], with copyright permission from nature springer
publisher, copyright 2020.
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in different concentration of ivermectin groups, with a dose-dependent relationship
(Figure 2D and E).
3.3 Effect of ivermectin on cell migration in ovarian cancers
Wound healing experiment was used to test the effect of ivermectin on cell
migration of ovarian cancer cells. The results showed that cell migration was sig-
nificantly inhibited in cells A2780 and TOV-21G after treatment of 20 μM and
30 μM ivermectin (Figure 3) [4].
3.4 Pharmaceutic molecular network predicted the association of ivermectin
with ROS and energy metabolism
Ingenuity Pathway Analysis (IPA) was used for pharmaceutic molecular net-
work analysis of ivermectin. The results showed that ivermectin was significantly
Figure 2.
Ivermectin blocked cell cycle progression (A, B, C) and promoted cell apoptosis (D, E) of ovarian cancer cells.
Reproduced from Li et al. [21], with copyright permission from nature springer publisher, copyright 2020.
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associated with reactive oxygen species (ROS) and energy metabolism pathways,
including pyruvate kinase muscle (PKM), oxoglutarate dehydrogenase L
(OGDHL), mitochondrially encoded NADH dehydrogenase 2 (ND2),
mitochondrially encoded NADH dehydrogenase 5 (ND5), CytB, and ubiquinolcy-
tochrome c reductase hinge protein (UQCRH) (Figure 4) [21]. Moreover, iver-
mectin directly regulated Rbp, CYP3A4, P2RX7, ABCB1, GLRB, ABCG2, P2RX4, P
glycoprotein, Abcb1b, strychnine, cytokine, and insulin; and indirectly regulated
TNF, APP, MAPK1, ERK1/2, MAPK3, MAPK13, ROS, NFKBIA, testosterone, and
STAT3 [21].
3.5 SILAC quantitative proteomics revealed the effects of ivermectin on key
proteins in energy metabolism pathways in ovarian cancer cells
SILAC quantitative proteomics was used to detect, identify, and quantify the
key protein alterations in energy metabolic pathways in ovarian cancer cells treated
with (SILAC: H) and without (SILAC: L) 20 μM ivermectin for 24 h (Table 1) [21].
This study found that ivermectin significantly reduced (i) the expression levels of
glycolysis-related enzymes, including ADH5, ENO1, GPI, GAPDH, LDHA, LDHB,
PFKP, and PKM; (ii) the Kreb’s cycle-related enzymes, including ACON, PCK2,
PDHB, MDH2, CS, IDH2, IDH3A, IDH3B, SUCLG2, and OGDHL; (iii) the
OXPHOS-related enzymes, including CYTB, UQCRH, COX17, COX1, COX6C,
COX4I1, COX2, COX7A2L, COX7A2, ATP6V0C, and ATP6; and (iv) the lactate
shuttle proteins MCT1 and MCT4, in ovarian cancer cells.
3.6 RT-qPCR and Western blot confirmed the effects of ivermectin on the key
molecules in energy metabolism pathways at the mRNA and protein levels
RT-qPCR analysis confirmed the mRNA expression alterations of key molecules
in energy metabolism pathways in ovarian cancer cells treated with ivermectin
(0 μM, 10 μM, 20 μM, and 30 μM) (Figure 5), and further western blot analysis
confirmed the protein expression alterations of those corresponding key molecules
(Figure 6) [21]. These key molecules included PFKP, and PKM in glycolysis path-
way, PDHB, CS, IDH2, IDH3A, IDH3B, and OGDHL in Kreb’s cycle pathway, ND2,
ND5, CYTB, and UQCRH in oxidative phosphorylation pathway, MCT1, and MCT4
in lactate shuttle. These results clearly showed that ivermectin regulated energy
metabolism pathways in ovarian cancer cells.
Figure 3.
Ivermectin inhibited cell migration of ovarian cancer cells TOV-21G relative to control cells A2780, analyzed
with wound healing experiments. Reproduced from Li et al. [4], with copyright permission from nature springer
publisher, copyright 2020.
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3.7 Ivermectin regulated lncRNA-EIF4A3-mRNA axis in ovarian cancer cells
Our quantitative mitochondrial proteomics data identified 1198 differentially
mitochondrial proteins (mtDEPs) in human ovarian cancer tissues relative to con-
trol ovary tissues [11, 23]. Six RNA-binding proteins among those 1198 mtDEPs
were identified, including EIF4A3, SFRS1, IGF2BP2, UPF1, C22ORF28, and
EWSR1. Of them, only EIF4A3 was predicted to bind to the mRNA of key molecules
in energy metabolism pathways. Further, Starbase predicted 3636 EIF4A3-biding
mRNAs in various cancer; and of them, 306 EIF4A3-binding mRNAs was associated
Figure 4.
Pharmaceutic molecular network predicted the associations of ivermectin with reactive oxygen species (ROS) and
energy metabolism pathways (A) Disease and functional analysis of ivermectin based on IPA database (B-G).
The association of ivermectin with PKM (B), OGDHL (C), ND2 (D), UQCRH (E), ND5 (F), and CYTB (G).
Reproduced from Li et al. [21], with copyright permission from nature springer publisher, copyright 2020.
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Intensity H Intensity L Ratio
H/L
Glycolysis pathway PFKAP PFKP ATP-dependent 6-phosphofructokinase, platelet type 0.00E
+00
14226000000 25587000000 0.54
H3BQ34 PKM Pyruvate kinase 7.46E-
03
10727000 0 +
ODPB PDHB Pyruvate dehydrogenase E1 component subunit beta, mitochondrial 0.00E
+00
407280000 1649500000 0.46
K4EN11 GAPDH GAPDH (Fragment) 0.00E
+00
0 0 /
ENOA ENO1 Alpha-enolase 0.00E
+00
54687000000 125660000000 0.44
F5GXY2 LDHA L-lactate dehydrogenase A chain (Fragment) 1.00E
+00
10379000 29470000 0.34
Q5U077 LDHB L-lactate dehydrogenase 0.00E
+00
27852000000 66990000000 0.42
A0A0A0MTS2 GPI Glucose-6-phosphate isomerase (Fragment) 1.00E
+00
56685000 138520000 0.44
Q6IRT1 ADH5 S-(hydroxymethyl)glutathione dehydrogenase 0.00E
+00
1308100000 3513700000 0.45





H3BRS6 ADPGK ADP-dependent glucokinase (Fragment) 5.31E-
04
11465000 18413000 0.69
AL1B1 ALDH1B1 Aldehyde dehydrogenase X, mitochondrial 0.00E
+00
69821000 196750000 0.45





















































Intensity H Intensity L Ratio
H/L
AL3A2 ALDH3A2 Aldehyde dehydrogenase family 3 member A2 0.00E
+00
225000000 394360000 0.55
AL9A1 ALDH9A1 4-trimethylaminobutyraldehyde dehydrogenase 0.00E
+00
529020000 1322400000 0.48
A0A024QZ64 ALDOC Fructose-bisphosphate aldolase 0.00E
+00
1104800000 2650700000 0.43
H0YDD4 DLAT Acetyltransferase component of pyruvate dehydrogenase complex (Fragment) 0.00E
+00
530720000 1251100000 0.46
A0A024R713 DLD Dihydrolipoyl dehydrogenase 0.00E
+00
632170000 1843800000 0.52
Q6FHV6 ENO2 ENO2 protein 0.00E
+00
618190000 2887100000 0.26
ENOB ENO3 Beta-enolase 0.00E
+00
215810000 482340000 0.59
B4DG62 HK1 cDNA FLJ56506, highly similar to Hexokinase-1 0.00E
+00
1617000000 4075800000 0.53
HKDC1 HKDC1 Hexokinase HKDC1 0.00E
+00
132850000 568430000 0.30
PCKGC PCK1 Phosphoenolpyruvate carboxykinase, cytosolic [GTP] 0.00E
+00
1267700 160370000 0.07
A0A384MTT2 PCK2 Epididymis secretory sperm binding protein 0.00E
+00
403190000 1032500000 0.56
A0A024RBX9 PDHA1 Pyruvate dehydrogenase E1 component subunit alpha 0.00E
+00
457490000 1353000000 0.49





































Intensity H Intensity L Ratio
H/L
A0A024R0Y5 PFKM ATP-dependent 6-phosphofructokinase 0.00E
+00
1677600000 3768800000 0.47
Q6P6D7 PGAM1 Phosphoglycerate mutase 0.00E
+00
11906000000 30409000000 0.36
A0A3B3ITK7 PGM1 Phosphoglucomutase-1 0.00E
+00
721450000 1641900000 0.43
PGM2 PGM2 Phosphoglucomutase-2 0.00E
+00
144180000 423580000 0.40
A0A024R5Z9 PKM2 Pyruvate kinase 1.00E
+00
35541000 125430000 0.54
Kreb’s cycle ODPB PDHB Pyruvate dehydrogenase E1 component subunit beta, mitochondrial 0.00E
+00
407280000 1649500000 0.46
B4DJV2 CS Citrate synthase 0.00E
+00
2428500000 5338700000 0.45
IDHP IDH2 Isocitrate dehydrogenase [NADP], mitochondrial 0.00E
+00
1281200000 2994300000 0.46
IDH3A IDH3A Isocitrate dehydrogenase [NAD] subunit alpha, mitochondrial 0.00E
+00
268600000 1119300000 0.40
A0A087WZN1 IDH3B Isocitrate dehydrogenase [NAD] subunit, mitochondrial 0.00E
+00
142630000 477180000 0.41
OGDHL OGDHL 2-oxoglutarate dehydrogenase-like, mitochondrial 0.00E
+00
17707000 119970000 0.56
O75944 ACON Aconitase (Fragment) 0.00E
+00
0 48304000 —




















































Intensity H Intensity L Ratio
H/L
Q0QF37 MDH2 Malate dehydrogenase (Fragment) 0.00E
+00
5856200000 14406000000 0.42
A0A024R325 SUCLG2 Succinate–CoA ligase [GDP-forming] subunit beta, mitochondrial 0.00E
+00
232210000 779800000 0.41
Q71UF1 ACO2 Aconitate hydratase, mitochondrial 1.00E
+00
0 12950000 —
A0A024R1Y2 ACLY ATP-citrate synthase 0.00E
+00
2033900000 4490700000 0.46
H0YDD4 DLAT Acetyltransferase component of pyruvate dehydrogenase complex (Fragment) 0.00E
+00
530720000 1251100000 0.46
A0A024R713 DLD Dihydrolipoyl dehydrogenase 0.00E
+00
632170000 1843800000 0.52
Q6IBS5 DLST DLST protein 0.00E
+00
601540000 1338700000 0.53
A0A0S2Z4C3 FH Epididymis secretory sperm binding protein (Fragment) 0.00E
+00
1498700000 3849500000 0.43
IDH3G IDH3G Isocitrate dehydrogenase [NAD] subunit gamma, mitochondrial 0.00E
+00
55446000 230380000 0.54
ODO1 OGDH 2-oxoglutarate dehydrogenase, mitochondrial 0.00E
+00
325090000 949610000 0.43
A0A494C101 PC Pyruvate carboxylase, mitochondrial (Fragment) 7.83E-
04
3454600 19685000 0.28
PCKGC PCK1 Phosphoenolpyruvate carboxykinase, cytosolic [GTP] 0.00E
+00
1267700 160370000 0.07





































Intensity H Intensity L Ratio
H/L
A0A024QZ30 SDHA Succinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrial 0.00E
+00
1096500000 2950800000 0.44
SDHB SDHB Succinate dehydrogenase [ubiquinone] iron–sulfur subunit, mitochondrial 0.00E
+00
143030000 516360000 0.37
D3DVH1 SDHC Succinate dehydrogenase complex, subunit C, integral membrane protein,




B7ZAF6 SUCLA2 Succinate–CoA ligase [ADP-forming] subunit beta, mitochondrial 0.00E
+00
114900000 726200000 0.33





D2Y6X2 ND5 NADH dehydrogenase subunit 5 (Fragment) 5.33E-
04
4125200 24591000 0.41
A0A1B0TCA9 CYTB Cytochrome b (Fragment) 3.59E-
03
53396000 59765000 0.55
Q567R0 UQCRH UQCRH protein 0.00E
+00
252050000 546900000 0.51
C9J8T6 COX17 Cytochrome c oxidase copper chaperone 0.00E
+00
7643200 53020000 0.36
Q6FGA0 COX7A2L COX7A2L protein 5.34E-
04
22802000 1280400 17.81
U3L4G0 ATP6 ATP synthase subunit a 0.00E
+00
193600000 355900000 0.73
X2C5C9 COX1 Cytochrome c oxidase subunit 1 7.89E-
04
21347000 57543000 0.38




















































Intensity H Intensity L Ratio
H/L
H3BNI4 ATP6V0C V-type proton ATPase proteolipid subunit 1.00E
+00
11819000 33788000 0.47
Q496I0 COX7A2 COX7A2 protein 0.00E
+00
223550000 687660000 0.32
COX6C COX6C Cytochrome c oxidase subunit 6C 0.00E
+00
24314000 57899000 0.34
COX41 COX4I1 Cytochrome c oxidase subunit 4 isoform 1, mitochondrial 0.00E
+00
1057000000 2524600000 0.40
AT12A ATP12A Potassium-transporting ATPase alpha chain 2 1.00E
+00
25608000 48153000 0.50
ATPG ATP5F1C ATP synthase subunit gamma, mitochondrial 0.00E
+00
610730000 1752800000 0.61
ATPD ATP5F1D ATP synthase subunit delta, mitochondrial 0.00E
+00
173290000 378660000 0.59
ATP5I ATP5ME ATP synthase subunit e, mitochondrial 0.00E
+00
139860000 416580000 0.28
ATPK ATP5MF ATP synthase subunit f, mitochondrial 0.00E
+00
146600000 369660000 0.57
E9PN17 ATP5MG ATP synthase subunit g, mitochondrial 0.00E
+00
501810000 1039800000 0.45
Q5QNZ2 ATP5PB ATP synthase F(0) complex subunit B1, mitochondrial 0.00E
+00
1074900000 2486300000 0.46
ATP5H ATP5PD ATP synthase subunit d, mitochondrial 0.00E
+00
525070000 965510000 0.39





































Intensity H Intensity L Ratio
H/L
VPP1 ATP6V0A1 V-type proton ATPase 116 kDa subunit a isoform 1 0.00E
+00
98038000 557300000 0.35
R4GN72 ATP6V0D1 V-type proton ATPase subunit d 1 0.00E
+00
258530000 806720000 0.31
VATA ATP6V1A V-type proton ATPase catalytic subunit A 0.00E
+00
1191800000 3218800000 0.37
VATB2 ATP6V1B2 V-type proton ATPase subunit B, brain isoform 0.00E
+00
583390000 2310600000 0.35
A0A024R9I0 ATP6V1C1 V-type proton ATPase subunit C 0.00E
+00
105790000 524300000 0.36
Q53Y06 ATP6V1E1 ATPase, H+ transporting, lysosomal 31 kDa, V1 subunit E isoform 1 0.00E
+00
226190000 457540000 0.46
A4D1K0 ATP6V1F V-type proton ATPase subunit F 0.00E
+00
72747000 287010000 0.62
A0A024R883 ATP6V1G1 V-type proton ATPase subunit G 0.00E
+00
121660000 150890000 0.58
A0A024R7X3 ATP6V1H V-type proton ATPase subunit H 0.00E
+00
33783000 166330000 0.37
COX15 COX15 Cytochrome c oxidase assembly protein COX15 homolog 0.00E
+00
52507000 160350000 0.47
A0A343FH12 COX3 Cytochrome c oxidase subunit 3 0.00E
+00
251800000 620670000 0.40
H3BNX8 COX5A Cytochrome c oxidase subunit 5A, mitochondrial 0.00E
+00
489640000 1451700000 0.67




















































Intensity H Intensity L Ratio
H/L
CX6B1 COX6B1 Cytochrome c oxidase subunit 6B1 0.00E
+00
278190000 1028600000 0.28
CY1 CYC1 Cytochrome c1, heme protein, mitochondrial 0.00E
+00
426190000 876770000 0.51
Q5T1Z0 LHPP Phospholysine phosphohistidine inorganic pyrophosphate phosphatase 9.74E-
03
0 20832000 —
D8VCQ0 ND4 NADH–ubiquinone oxidoreductase chain 4 (Fragment) 3.36E-
03
3604800 7493900 0.44





NDUAD NDUFA13 NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13 0.00E
+00
43461000 261780000 0.34
NDUA2 NDUFA2 NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 2 0.00E
+00
35677000 165030000 0.24
NDUA4 NDUFA4 Cytochrome c oxidase subunit NDUFA4 0.00E
+00
99542000 1041400000 0.28
NDUA5 NDUFA5 NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 5 0.00E
+00
126370000 440540000 0.46
NDUA8 NDUFA8 NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 8 0.00E
+00
75771000 226560000 0.33





H3BNK3 NDUFAB1 Acyl carrier protein (Fragment) 0.00E
+00
91383000 220140000 0.41





































Intensity H Intensity L Ratio
H/L
H3BPJ9 NDUFB10 NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 10 0.00E
+00
68400000 353550000 0.41





C9JKQ2 NDUFB3 NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 3 (Fragment) 7.84E-
04
19660000 91217000 0.33
NDUB4 NDUFB4 NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 4 0.00E
+00
15764000 129660000 0.40
NDUB8 NDUFB8 NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 8, mitochondrial 0.00E
+00
38897000 134110000 0.34
A0A3B3IT57 NDUFB9 NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 9 0.00E
+00
47909000 178250000 0.26
E5KRK5 NDUFS1 Mitochondrial NADH–ubiquinone oxidoreductase 75 kDa subunit 0.00E
+00
87635000 1424000000 0.27
NDUS2 NDUFS2 NADH dehydrogenase [ubiquinone] iron–sulfur protein 2, mitochondrial 0.00E
+00
255210000 555800000 0.40
NDUS3 NDUFS3 NADH dehydrogenase [ubiquinone] iron–sulfur protein 3, mitochondrial 0.00E
+00
303550000 1007100000 0.38





































































Intensity H Intensity L Ratio
H/L
G3V0I5 NDUFV1 NADH dehydrogenase [ubiquinone] flavoprotein 1, mitochondrial 0.00E
+00
25550000 98424000 0.34
Q9UEH5 NDUFV2 24-kDa subunit of complex I (Fragment) 0.00E
+00
120810000 407130000 0.33
IPYR2 PPA2 Inorganic pyrophosphatase 2, mitochondrial 0.00E
+00
815730000 1743800000 0.42
A0A024QZ30 SDHA Succinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrial 0.00E
+00
1096500000 2950800000 0.44
SDHB SDHB Succinate dehydrogenase [ubiquinone] iron–sulfur subunit, mitochondrial 0.00E
+00
143030000 516360000 0.37
D3DVH1 SDHC Succinate dehydrogenase complex, subunit C, integral membrane protein,




A0A024R5E5 TCIRG1 V-type proton ATPase subunit a 0.00E
+00
139450000 227300000 0.73
QCR9 UQCR10 Cytochrome b-c1 complex subunit 9 0.00E
+00
260330000 491890000 0.52
QCR7 UQCRB Cytochrome b-c1 complex subunit 7 0.00E
+00
208330000 523300000 0.37
QCR1 UQCRC1 Cytochrome b-c1 complex subunit 1, mitochondrial 0.00E
+00
1326400000 3772100000 0.43
QCR2 UQCRC2 Cytochrome b-c1 complex subunit 2, mitochondrial 0.00E
+00
1718400000 3636100000 0.43
A0A384NPX8 UQCRFS1 Cytochrome b-c1 complex subunit Rieske, mitochondrial 0.00E
+00
79904000 211540000 0.34





































Intensity H Intensity L Ratio
H/L
Lactate shuttle B4E106 MCT1 cDNA FLJ53399, highly similar to Monocarboxylate transporter 1 0.00E
+00
23799000 115420000 0.53




SILAC quantitative proteomics revealed the protein expression changes of key molecules in energy metabolic pathways in ovarian cancer cells TOV-21G treated with (SILAC: H) and without
(SILAC: L) 20 μM ivermectin for 24 h. - means the protein expressed in L group but not in H group. + means the protein expressed in H group but not in L group. /means the protein with
expressed value 0 in both H and L groups. Ratio H/L means the ratio of the ivermectin-treated group (SILAC: H) to the no ivermectin-treated group (SILAC: L). Reproduced from Li et al. [21],














































with ovarian cancer survival rate. Among 306 EIF4A3-binding mRNAs, the protein
expressions of 116 EIF4A3-binding mRNAs and EIF4A3 were found to be inhibited
by ivermectin, identified by SILAC quantitative proteomics in ovarian cancer cells
treated with and without ivermectin (Table 2) [4].
Moreover, TCGA transcriptomics analysis found that 16 lncRNAs had binding
sites with EIF4A3 and associated with ovarian cancer survival rate, including
SNHG3, HCG15, PDCD4-AS1, KIF9-AS1, ZNRF3-AS1, ZNF674-AS1, LINC00565,
SOS1-IT1, WWTR1-AS1, PLCH1-AS1, LINC00517, STARD13-IT1, LEMD1-AS1,
AL109767.1, HOXC-AS3, and LBX2-AS1 [23]. Further, RT-qPCR analysis of these 16
lncRNA expressions in ovarian cancer cells treated with ivermectin (0 μM, 10 μM,
20 μM, and 30 μM) compared to control cells, which found 9 lncRNAs (PDCD4-
AS1, ZNRF3-AS1, HCG15, KIF9-AS1, LINC00565, ZNF674-AS1, AL109767.1, SOS1-
IT1, and LBX2-AS1) were significantly affected by ivermectin (Figure 7) [4].
These findings clearly demonstrated that ivermectin regulated lncRNA-EIF4A3-
mRNA axis in ovarian cancer cells, and these mRNAs included the key molecules in
energy metabolism pathways in ovarian cancer cells.
3.8 The prognostic model of ivermectin-related three-lncRNA signature for
ovarian cancers identified and optimized by lasso regression
Based on those nine ivermectin-mediated lncRNAs in ovarian cancers,
survival analysis and lasso regression were used to identify and optimize the
prognostic model of ivermectin-related three-lncRNA signature (ZNRF3-AS1,
Figure 5.
RT-qPCR confirmed the effects of ivermectin on the mRNA expressions of key molecules in the energy
metabolism pathways in ovarian cancer cells (a-f). The effects of different concentration of ivermectin (0, 10,
20, and 30 μM) on mRNA expressions of PFKP, PKM, CS, PDHB, IDH2, IDH3A, IDH3B, OGDHL, ND5,
ND2, CYTB, UQCRH, MCT1, and MCT4. n = 3. *p < 0.05, **p < 0.01, ***p < 0.001. Reproduced from Li
et al. [21], with copyright permission from nature springer publisher, copyright 2020.
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SOS1-IT1, and LINC00565) (Figure 8) [4]. This prognostic model was significantly
related to overall survival and clinicopathologic characteristics in ovarian cancer
patients [4], which might benefit for prognostic assessment and personalized drug
therapy toward 3P medicine practice in ovarian cancer.
Figure 6.
Western blot confirmed the effects of ivermectin on the protein expressions of key molecules in the energy
metabolism pathways in ovarian cancer cells. n = 3. *p < 0.05, **p < 0.01, ***p < 0.001. Reproduced from Li
et al. [21], with copyright permission from nature springer publisher, copyright 2020.
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Protein IDs Protein names Gene names Q-value Score Intensity H Intensity L Ratio H/L
A0A0S2Z4C6 Serine/threonine-protein phosphatase 2B catalytic subunit alpha isoform PPP3CA 0 106 450040000 2.321E+09 0.17
A0A024R7B0 Ubiquitin-like protein 5 UBL5 0 3 33400000 156360000 0.20
A0A024R9A9 Ubiquitin-conjugating enzyme E2 T UBE2T 0 7 54580000 216150000 0.22
A0A494C101 Pyruvate carboxylase;Pyruvate carboxylase, mitochondrial PC 0 3 3454600 19685000 0.28
A0A1W2PNM1 Hydroxyacyl-coenzyme A dehydrogenase, mitochondrial HADH 0 11 85389000 332200000 0.30
Q496I0 Cytochrome c oxidase subunit 7A2, mitochondrial COX7A2 0 10 223550000 687660000 0.32
Q149N6 Dedicator of cytokinesis protein 4 DOCK4 0 4 2402200 12153000 0.33
Q15036 Sorting nexin-17 SNX17 0 9 2545600 64295000 0.33
J3KN67 Tropomyosin alpha-3 chain TPM3 0 3 44208000 225430000 0.34
Q8WZ82 Ovarian cancer-associated gene 2 protein OVCA2 0 8 22175000 92294000 0.34
G3V0I5 NADH dehydrogenase [ubiquinone] flavoprotein 1, mitochondrial NDUFV1 0 9 25550000 98424000 0.34
J3QLR8 28S ribosomal protein S23, mitochondrial MRPS23 0 8 59957000 127510000 0.35
J3KSI8 28S ribosomal protein S7, mitochondrial MRPS7 0 9 56198000 98108000 0.35
B4DP80 NAD(P)H-hydrate epimerase APOA1BP 0 47 81014000 347980000 0.37
C9JFE4 COP9 signalosome complex subunit 1 GPS1 0 25 189930000 447320000 0.38
Q9Y3B7 39S ribosomal protein L11, mitochondrial MRPL11 0 5 17279000 5213500 0.38
Q9Y333 U6 snRNA-associated Sm-like protein LSm2 LSM2 0 23 188570000 423780000 0.38
P63261 Actin ACTG1 0 212 3.864E+09 1.674E+10 0.38
Q07954 Prolow-density lipoprotein receptor-related protein 1 LRP1 0 5 3971000 52428000 0.38
Q68E01 Integrator complex subunit 3 INTS3 0 11 32873000 113610000 0.38
K7EKI4 39S ribosomal protein L4, mitochondrial MRPL4 0 9 41947000 121900000 0.39































Protein IDs Protein names Gene names Q-value Score Intensity H Intensity L Ratio H/L
A0A0S2Z4T1 DNA replication licensing factor MCM3 MCM3 0 187 1.033E+09 3.186E+09 0.40
A0A0S2Z3L0 Electron transfer flavoprotein subunit alpha, mitochondrial ETFA 0 44 623280000 1.382E+09 0.40
Q8NFH5 Nucleoporin NUP53 NUP35 0 81 206630000 398870000 0.40
Q5T7C4 High mobility group protein B1 HMGB1 0 98 2.916E+09 1.141E+10 0.40
A0A024R8M4 Phosphoribosyl pyrophosphate synthase-associated protein 1 PRPSAP1 0 20 88227000 200670000 0.41
G3V2D5 Zinc finger protein 36, C3H1 type-like 1 ZFP36L1 0 18 6238500 15019000 0.41
A6NMQ3 Alpha-endosulfine ENSA 0 5 80231000 206330000 0.41
A0A0J9YYL3 Poly(U)-binding-splicing factor PUF60 PUF60 0 135 468910000 1.281E+09 0.42
A0A481SVJ4 Matrix-remodeling-associated protein 7 MXRA7 0 2 4184200 24167000 0.42
J3KTF8 Rho GDP-dissociation inhibitor 1 ARHGDIA 0 56 1.44E+09 3.59E+09 0.42
P49736 DNA replication licensing factor MCM2 MCM2 0 90 937140000 2.544E+09 0.43
K7EJH0 Kinetochore protein Spc24 SPC24 0 7 91278000 196000000 0.43
Q9BRA2 Thioredoxin domain-containing protein 17 TXNDC17 0 38 745240000 1.838E+09 0.43
P15531 Nucleoside diphosphate kinase A NME1 0 20 312380000 966090000 0.43
D3DVA5 Rho guanine nucleotide exchange factor 2 ARHGEF2 0 16 26979000 80246000 0.44
B7ZM10 Exportin-6 XPO6 0 7 7924200 14822000 0.44
G8JLD3 ELKS/Rab6-interacting/CAST family member 1 ERC1 0 44 179630000 428430000 0.44
B2R7W3 Breast carcinoma amplified sequence 2 BCAS2 0 15 38190000 177190000 0.44
C9JJ19 28S ribosomal protein S34, mitochondrial MRPS34 0 10 69862000 158490000 0.44
A0A0S2Z4Q4 Hepatocyte growth factor-regulated tyrosine kinase substrate HGS 0 10 52165000 121060000 0.44
Q53Y51 D-dopachrome decarboxylase DDT 0 36 259770000 672160000 0.45














































Protein IDs Protein names Gene names Q-value Score Intensity H Intensity L Ratio H/L
Q6FHQ0 Histone-binding protein RBBP7 RBBP7 0 160 2.134E+09 4.792E+09 0.45
P29144 Tripeptidyl-peptidase 2 TPP2 0 173 523060000 1.368E+09 0.45
Q9UP83 Conserved oligomeric Golgi complex subunit 5 COG5 0 5 14333000 32372000 0.46
E9PID8 Cleavage stimulation factor subunit 2 CSTF2 0 39 128240000 239460000 0.46
A0A024R496 Calcium-binding protein 39 CAB39 0 24 198430000 418650000 0.46
Q6IAP9 U4/U6 small nuclear ribonucleoprotein Prp4 PRPF4 0 42 168190000 621480000 0.46
A0A024RB32 Prostaglandin E synthase 3 PTGES3 0 110 2.02E+09 5.058E+09 0.46
E9PMG1 RalBP1-associated Eps domain-containing protein 1 REPS1 0 8 13894000 28102000 0.46
P28066 Proteasome subunit alpha type-5 PSMA5 0 107 1.677E+09 4.011E+09 0.46
I3L2G3 Ketosamine-3-kinase FN3KRP 0 7 16246000 54477000 0.46
A0A0S2Z4Z0 RNA-binding protein 14 RBM14 0 83 606470000 1.446E+09 0.46
A8K651 Complement component 1 Q subcomponent-binding protein, mitochondrial C1QBP 0 109 3.184E+09 7.587E+09 0.47
O60506 Heterogeneous nuclear ribonucleoprotein Q SYNCRIP 0 121 3.657E+09 8.092E+09 0.47
P42345 Serine/threonine-protein kinase mTOR MTOR 0 14 52206000 144780000 0.47
A8K878 Mesencephalic astrocyte-derived neurotrophic factor MANF 0 38 604460000 1.613E+09 0.47
A0MNN4 Shwachman-Bodian-Diamond syndrome isoform 1 SMU1 0 60 321320000 679840000 0.47
A0A024R8B1 TBC1 domain family member 13 TBC1D13 0 4 20484000 74249000 0.47
Q9UHR4 Brain-specific angiogenesis inhibitor 1-associated protein 2-like protein 1 BAIAP2L1 0 6 21391000 41855000 0.47
Q5SRT3 Chloride intracellular channel protein 1 CLIC1 0 299 1.295E+10 2.924E+10 0.47
A0A0S2Z5I7 Ribosome maturation protein SBDS SBDS 0 16 344540000 808860000 0.48
Q13505 Metaxin-1 MTX1 0 10 45737000 109770000 0.49































Protein IDs Protein names Gene names Q-value Score Intensity H Intensity L Ratio H/L
Q53HN4 DNA fragmentation factor subunit alpha DFFA 0 31 272390000 539710000 0.50
P38919 Eukaryotic initiation factor 4A-III EIF4A3 0 77 1.57E+09 3.534E+09 0.50
B4DY09 Interleukin enhancer-binding factor 2 ILF2 0 96 2.642E+09 6.06E+09 0.50
E9PF19 Transducin beta-like protein 2 TBL2 0 28 109400000 213970000 0.50
A0A087WXS7 ATPase ASNA1 ASNA1 0 63 850190000 1.755E+09 0.51
O43324 Eukaryotic translation elongation factor 1 epsilon-1 EEF1E1 0 29 662460000 1.236E+09 0.51
Q15717 ELAV-like protein 1 ELAVL1 0 92 2.093E+09 4.32E+09 0.51
Q9UMS4 Pre-mRNA-processing factor 19 PRPF19 0 127 897150000 2.364E+09 0.52
P14324 Farnesyl pyrophosphate synthase FDPS 0 26 1.03E+09 2.078E+09 0.52
P28070 Proteasome subunit beta type-4 PSMB4 0 25 512090000 1E+09 0.52
Q0VGA5 SARS protein SARS 0 149 1.216E+09 2.647E+09 0.53
A0A024RCX8 Peptidyl-prolyl cis-trans isomerase-like 1 PPIL1 0 10 122810000 365070000 0.53
Q9H8H0 Nucleolar protein 11 NOL11 0 5 22443000 80063000 0.54
E7EX90 Dynactin subunit 1 DCTN1 0 131 823150000 1.803E+09 0.54
Q05D78 Double-strand break repair protein MRE11A MRE11A 0 3 24064000 56350000 0.54
H7C440 DIS3-like exonuclease 2 DIS3L2 0 4 13696000 21117000 0.54
Q9Y3U8 60S ribosomal protein L36 RPL36 0 34 544540000 770200000 0.55
Q9UJZ1 Stomatin-like protein 2, mitochondrial STOML2 0 119 866230000 1.683E+09 0.55
Q567R6 Single-stranded DNA-binding protein, mitochondrial SSBP1 0 60 561820000 1.077E+09 0.55
Q15084 Protein disulfide-isomerase A6 PDIA6 0 323 1.201E+10 2.023E+10 0.56
Q15645 Pachytene checkpoint protein 2 homolog TRIP13 0 27 276670000 492930000 0.56














































Protein IDs Protein names Gene names Q-value Score Intensity H Intensity L Ratio H/L
Q9NPD3 Exosome complex component RRP41 EXOSC4 0 25 239980000 490570000 0.57
Q9UHB9 Signal recognition particle subunit SRP68 SRP68 0 68 343910000 687640000 0.57
F5H0P4 Porphobilinogen deaminase HMBS 0 9 38322000 129490000 0.57
Q96SB4 SRSF protein kinase 1 SRPK1 0 49 123510000 199050000 0.57
Q9Y6W5 Wiskott-Aldrich syndrome protein family member 2 WASF2 0 22 69082000 151250000 0.57
A0A024R8S5 Protein disulfide-isomerase P4HB 0 300 1.656E+10 2.799E+10 0.57
A0A2X0SF71 Rho GTPase-activating protein 17 ARHGAP17 0 28 59467000 116590000 0.58
P09496 Clathrin light chain A CLTA 0 7 508650000 765700000 0.58
R4GMU1 GDH/6PGL endoplasmic bifunctional protein H6PD 0 4 20789000 34525000 0.60
Q8NCN5 Pyruvate dehydrogenase phosphatase regulatory subunit, mitochondrial PDPR 0 3 10312000 28116000 0.60
Q8WY22 BRI3-binding protein BRI3BP 0.01 2 5099700 6146700 0.62
Q6IB29 Probable rRNA-processing protein EBP2 EBNA1BP2 0 6 30468000 61825000 0.62
O15031 Plexin-B2 PLXNB2 0 18 30986000 221240000 0.62
C9JYQ9 60S ribosomal protein L22-like 1 RPL22L1 0 6 616860000 1.011E+09 0.66
Q9UNS2 COP9 signalosome complex subunit 3 COPS3 0 56 157900000 294180000 0.66
A0A0G2JNZ5 Glucosylceramidase GBA 0 6 118570000 187510000 0.67
A0A140VK17 EH domain-binding protein 1 EHBP1 0 4 6547700 17018000 0.71
F5GWG3 Retinoic acid-induced protein 3 GPRC5A 0 11 149190000 185790000 0.76
S4R3V8 Lipolysis-stimulated lipoprotein receptor LSR 0 4 26182000 34332000 1.05
Q9NWT6 Hypoxia-inducible factor 1-alpha inhibitor HIF1AN 0 17 0 46940000 NaN
B7ZBQ1 Mediator of RNA polymerase II transcription subunit 20 MED20 0.01 2 0 18220000 NaN































Protein IDs Protein names Gene names Q-value Score Intensity H Intensity L Ratio H/L
P52815 39S ribosomal protein L12, mitochondrial MRPL12 0.01 2 0 0 NaN
A0A024R1I3 Pyridoxal phosphate phosphatase PDXP 0 6 0 40714000 NaN
A0A2R8YDS2 Ras/Rap GTPase-activating protein SynGAP SYNGAP1 0 2 0 18400000 NaN
J3KQA0 Synaptotagmin-1 SYT1 0 26 0 339450000 NaN
Q5W0C6 Torsin-3A TOR3A 0 3 0 16493000 NaN
B4DSK7 Mediator of RNA polymerase II transcription subunit 1 MED1 0 2 0 14356000 NaN
Q99549 M-phase phosphoprotein 8 MPHOSPH8 0 12 0 15782000 NaN
Table 2.
The proteins of 116 EIF4A3-biding mRNAs and EIF4A3 were inhibited by ivermectin, identified with SILAC quantitative proteomics in ovarian cancer cells treated with (H) and without (L)















































Ivermectin, as an old, common, and classic anti-parasite drug, has demonstrated
its effective in vitro anti-cancer efficiency for ovarian cancer. Ivermectin significantly
inhibited cell proliferation, growth and migration, blocked cell cycle progression,
Figure 7.
RT-qPCR analysis revealed the effects of ivermectin on lncRNAs in ovarian cancers relative to control cells.
Reproduced from Li et al. [4], with copyright permission from nature springer publisher, copyright 2020.
Figure 8.
Lasso regression identified and optimized the prognostic model of ivermectin-related three-lncRNA signature in
ovarian cancers. (A and B). Lasso regression complexity is controlled by lambda using the glmnet R package.
(C). Overall survival analysis of three-lncRNA signature between high-risk and low-risk groups. Reproduced
from Li et al. [4], with copyright permission from nature springer publisher, copyright 2020.
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and promoted cell apoptosis of human ovarian cancer cells. Drug pathway network
analysis of ivermectin revealed that it was significantly related to the key molecules of
four energy metabolism pathways, and RT-qPCR and immunoaffinity blot analyses
found that ivermectin significantly regulated these key molecules for those energy
metabolism pathways, including PFKP in glycolysis, IDH2 and IDH3B in Kreb’s cycle,
ND2, ND5, CYTB, and UQCRH in oxidative phosphorylation, and MCT1 and MCT4
in lactate shuttle. The integrative analysis of TCGA transcriptomics andmitochondrial
proteomics in ovarian cancer revealed that 16 survival-related lncRNAs were medi-
ated by ivermectin, which were further confirmed with RT-qPRC in human ovarian
cancer cells. SILAC quantitative proteomics analysis revealed that the expressions of
RNA-binding protein EIF4A3 and 116 EIF4A3-interacted genes were extensively
inhibited by ivermectin. Those 116 EIF4A3-interacted proteins included those key
molecules in four energy metabolism pathways, and those lncRNAs regulated
EIF4A3-mRNA axes. Thus, ivermectin mediated lncRNA-EIF4A3-mRNA axes in
ovarian cancer to exert its anticancer activities. Moreover, lasso regression identified
the prognostic model of ivermectin-related three-lncRNA signature (ZNRF3-AS1,
SOS1-IT1, and LINC00565), which was significantly associated with overall survival
and clinicopathologic characteristics of ovarian cancer patients. These ivermectin-
related molecular pattern alterations benefit for prognostic assessment and personal-
ized drug therapy in the context of 3P medicine practice in ovarian cancer.
Moreover, one must realize that these achieved data about the anti-cancer
activities of ivermectin in ovarian cancers are derived from the in vitro cell models.
It is necessary to expand it into the in vivo animal experiments and pre-clinical and
clinical experiments for its real application in ovarian cancers.
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